Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

NCT06916767 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Relapsed CLL
Refractory CLL
Refractory Lymphoma

Interventions

DRUG: BAFF CAR-T
DRUG: Obinutuzumab
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

Paolo Caimi, MD

Collaborators

[object Object]